Introduction
During the outbreak of Middle East respiratory syndrome in South Korea in 2015, there was a striking decrease in low-acuity disease presentations (45.2%) to emergency departments (EDs). In addition, a lesser but notable decrease in visits due to stroke (16.6%) and myocardial infarction (14%) occurred.1 Similar declines in admissions of non-vascular illnesses, stroke and cardiovascular disease have also been observed in EDs during the recent COVID-19 pandemic.2 The number of cardiac catheterisation laboratory ST-segment elevation myocardial infarction activations decreased by 38% in the USA and 40% in Spain as the pandemic spread.3 4 There was also a reported decline in the number of strokes in Piacenza, a city of 280 000 inhabitants and an important epicentre of the disease in Northern Italy, with monthly admissions decreasing from an average of 51 cases to only 6 over a 5-week period.5 Two larger studies from China and Spain also reported an estimated 25% decrease in patients who had a stroke presenting to EDs during the peak weeks of the pandemic.6 7 Moreover, two recent reports from the USA and Brazil report a decrease in transient ischaemic attacks (TIAs) and minor strokes during the pandemic.8 9
Although the decrease in minor ailments and trauma-related ED visits may be due to a fear of exposure to the virus, the reasons behind the significant drops in visits due to major acute cardiovascular and cerebrovascular events remain unclear. Paradoxically, recent reports are beginning to highlight an association between COVID-19 and a heightened coagulation state, resulting in an increased risk of severe stroke in younger patients.10
Prospective hospital-based or community registries are critical when studying the effects of pandemics on the rates of admissions due to vascular diseases.11 Registries may also provide important insights pertaining to time-sensitive healthcare delivery metrics, such as door-to-intervention times, and shed light on treatment delays real time, as was recently observed in the treatment of myocardial infarctions in Hong Kong.12 Similarly, concerns over delays in time-sensitive management of ischaemic stroke during the COVID-19 pandemic continue to increase.